Assessing the reporting quality of early phase dose-finding trials

被引：7
|
作者：
Yap, C. [1 ]
Solovyeva, O. [2 ]
Yin, Z. [2 ]
Martin, J. [3 ]
Manickavasagar, T. [3 ]
Weir, C. [4 ]
Lee, S. [5 ]
Dimairo, M. [6 ]
Liu, R. [7 ]
Kightley, A. [8 ]
de Bono, J. S. [9 ]
机构：
[1] ICR Inst Canc Res, Clin Trials Biostat Dept, North Site, London, England
[2] Inst Canc Res, Clin Trials & Stat Unit, London, England
[3] Inst Canc Res, Drug Dev Unit, London, England
[4] Univ Edinburgh, Edinburgh Clin Trials Unit, Edinburgh, Midlothian, Scotland
[5] Columbia Univ, Irving Med Ctr, New York, NY USA
[6] Univ Sheffield, Clin Trials Res Unit, Sheffield, S Yorkshire, England
[7] Bristol Meyers Squibb, Oncol, New York, NY USA
[8] Patient & Publ Involvement Partner, Lichfield, England
[9] ICR Inst Canc Res, Drug Dev Unit, London, England
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.01.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
53P
引用
收藏
页码：S24 / S24
页数：1
相关论文
共 50 条
  • [31] Design optimization for dose-finding trials: a review
    Aouni, Jihane
    Bacro, Jean Noel
    Toulemonde, Gwladys
    Colin, Pierre
    Darchy, Loic
    Sebastien, Bernard
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2020, 30 (04) : 662 - 673
  • [32] Implementing and assessing Bayesian response-adaptive randomisation for backfilling in dose-finding trials
    Pin, Lukas
    Villar, Sofia S.
    Dehbi, Hakim-Moulay
    CONTEMPORARY CLINICAL TRIALS, 2024, 142
  • [33] An adaptive gBOIN design with shrinkage boundaries for phase I dose-finding trials
    Mu, Rongji
    Hu, Zongliang
    Xu, Guoying
    Pan, Haitao
    BMC MEDICAL RESEARCH METHODOLOGY, 2021, 21 (01)
  • [34] An adaptive gBOIN design with shrinkage boundaries for phase I dose-finding trials
    Rongji Mu
    Zongliang Hu
    Guoying Xu
    Haitao Pan
    BMC Medical Research Methodology, 21
  • [35] Bayesian hybrid dose-finding design in phase I oncology clinical trials
    Yuan, Ying
    Yin, Guosheng
    STATISTICS IN MEDICINE, 2011, 30 (17) : 2098 - 2108
  • [36] Dose-finding in phase I clinical trials based on toxicity probability intervals
    Ji, Yuan
    Li, Yisheng
    Bekele, B. Nebiyou
    CLINICAL TRIALS, 2007, 4 (03) : 235 - 244
  • [37] Dose-Finding Trials Optimizing Phase 2 Data in the Drug Development Process
    Viele, Kert
    Connor, Jason T.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (21): : 2294 - 2295
  • [38] Competing designs for drug combination in phase I dose-finding clinical trials
    Riviere, M. -K.
    Dubois, F.
    Zohar, S.
    STATISTICS IN MEDICINE, 2015, 34 (01) : 1 - 12
  • [39] Adaptive dose-finding based on safety and feasibility in early-phase clinical trials of adoptive cell immunotherapy
    Wages, Nolan A.
    Fadul, Camilo E.
    CLINICAL TRIALS, 2020, 17 (02) : 157 - 165
  • [40] Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study
    Solovyeva, Olga
    Dimairo, Munyaradzi
    Weir, Christopher J.
    Hee, Siew Wan
    Espinasse, Aude
    Ursino, Moreno
    Patel, Dhrusti
    Kightley, Andrew
    Hughes, Sarah
    Jaki, Thomas
    Mander, Adrian
    Evans, Thomas R. Jeffry
    Lee, Shing
    Hopewell, Sally
    Rantell, Khadija Rerhou
    Chan, An-Wen
    Bedding, Alun
    Stephens, Richard
    Richards, Dawn
    Roberts, Lesley
    Kirkpatrick, John
    de Bono, Johann
    Yap, Christina
    BMC MEDICINE, 2023, 21 (01)
12345